Quantification of erufosine, the first intravenously applicable alkylphosphocholine, in human plasma by isotope dilution liquid chromatography-tandem mass spectrometry using a deuterated internal standard

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 869, Issue 1-2, 2008, Pages 16-19

  Lindner, Lars H ^a,b   Eibl, Hansjoerg ^c   Hossann, Martin ^a   Vogeser, Michael ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

Erufosine; Isotope dilution; Liquid chromatography tandem mass spectrometry (LC MS MS)

Indexed keywords

LIQUID CHROMATOGRAPHY; MASS SPECTROMETERS; PHARMACOKINETICS; PLASMA (HUMAN); PRECIPITATION (CHEMICAL); PROTEINS;

ALKYLPHOSPHOCHOLINE; ERUFOSINE; ISOTOPE DILUTION; REVERSED PHASE CHROMATOGRAPHY;

DRUG PRODUCTS;

ALKYL GROUP; DEUTERIUM; ERUFOSINE; PHOSPHORYLCHOLINE;

ANALYTIC METHOD; ARTICLE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; ISOTOPE DILUTION ASSAY; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; STANDARD; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

CHROMATOGRAPHY, LIQUID; DEUTERIUM; HUMANS; INDICATOR DILUTION TECHNIQUES; INJECTIONS, INTRAVENOUS; PHOSPHORIC ACID ESTERS; QUATERNARY AMMONIUM COMPOUNDS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 44749084003     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2008.05.007     Document Type: Article

References (19)

1. In: Eibl H., Hilgard P., and Unger C. (Eds). Alkylphosphocholines: New Drugs in Cancer Therapy, Prog. Exp. Tumor Res (1992), Karger, Basel
2. Oberle C., Massing U., and Krug H.F. Biol. Chem. 386 (2005) 237
3. Gajate C., and Mollinedo F. Blood 109 (2007) 711
4. Unger C., Peukert M., Sindermann H., Hilgard P., Nagel G., and Eibl H. Cancer Treat. Rev. 17 (1990) 243
5. Leonard R., Hardy J., van Tienhoven G., Houston S., Simmonds P., David M., and Mansi J. J. Clin. Oncol. 19 (2001) 4150
6. Kuhlencord A., Maniera T., Eibl H., and Unger C. Antimicrob. Agents Chemother. 36 (1992) 1630
7. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., and Berman J. N. Engl. J. Med. 347 (2002) 1739
8. Verweij J., Krzemieniecki K., Kok T., Poveda A., van Pottelsberghe C., van Glabbeke M., and Mouridsen H. Eur. J. Cancer 29A (1993) 208
9. Planting A.S., Stoter G., and Verweij J. Eur. J. Cancer 29A (1993) 518
10. Leighl N.B., Dent S., Clemons M., Vandenberg T.A., Tozer R., Warr D.G., Crump R.M., Hedley D., Pond G.R., Dancey J.E., and Moore M.J. Breast Cancer Res. Treat. 26 (2007) 26
11. Bailey H.H., Mahoney M.R., Ettinger D.S., Maples W.J., Fracasso P.M., Traynor A.M., Erlichman C., and Okuno S.H. Cancer 107 (2006) 2462
12. Erdlenbruch B., Jendrossek V., Gerriets A., Vetterlein F., Eibl H., and Lakomek M. Cancer Chemother. Pharmacol. 44 (1999) 484
13. Thaler A., Hottkowitz T., and Eibl H. Chem. Phys. Lipids 107 (2000) 131
14. Wieder T., Fritsch M., Haase A., and Geilen C.C. J. Chromatogr. B Biomed. Sci. Appl. 652 (1994) 9
15. Woo E.W., Messmann R., Sausville E.A., and Figg W.D. J. Chromatogr. B Biomed. Sci. Appl. 759 (2001) 247
16. Fiegl M., Lindner L.H., Juergens M., Eibl H., Hiddemann W., and Braess J. Cancer Chemother. Pharmacol. 6 (2007) 6
17. Rubel A., Handrick R., Lindner L.H., Steiger M., Eibl H., Budach W., Belka C., and Jendrossek V. Radiat. Oncol. 1 (2006) 6
18. Crul M., Rosing H., de Klerk G.J., Dubbelman R., Traiser M., Reichert S., Knebel N.G., Schellens J.H., Beijnen J.H., and ten Bokkel Huinink W.W. Eur. J. Cancer 38 (2002) 1615
19. Van Ummersen L., Binger K., Volkman J., Marnocha R., Tutsch K., Kolesar J., Arzoomanian R., Alberti D., and Wilding G. Clin. Cancer Res. 10 (2004) 7450